4.7 Article

Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers

Journal

BIOLOGICAL PSYCHIATRY
Volume 86, Issue 10, Pages 792-800

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2019.05.019

Keywords

Behavior; Emotion; LSD; Microdosing; Mood; Psychopharmacology

Funding

  1. National Institute of General Medical Sciences [2T32GM007281]
  2. National Institute on Drug Abuse [T32DA043469, DA02812]

Ask authors/readers for more resources

BACKGROUND: Numerous anecdotal reports suggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing, improves mood and cognitive function. These effects are consistent both with the known actions of LSD on serotonin receptors and with limited evidence that higher doses of LSD (100-200 mu g) positively bias emotion processing. Yet, the effects of such subthreshold doses of LSD have not been tested in a controlled laboratory setting. As a first step, we examined the effects of single very low doses of LSD (0-26 mu g) on mood and behavior in healthy volunteers under double-blind conditions. METHODS: Healthy young adults (N = 20) attended 4 laboratory sessions during which they received 0 (placebo), 6.5, 13, or 26 mu g of LSD in randomized order at 1-week intervals. During expected peak drug effect, they completed mood questionnaires and behavioral tasks assessing emotion processing and cognition. Cardiovascular measures and body temperature were also assessed. RESULTS: LSD produced dose-related subjective effects across the 3 doses (6.5, 13, and 26 mu g). At the highest dose, the drug also increased ratings of vigor and slightly decreased positivity ratings of images with positive emotional content. Other mood measures, cognition, and physiological measures were unaffected. CONCLUSIONS: Single microdoses of LSD produced orderly dose-related subjective effects in healthy volunteers. These findings indicate that a threshold dose of 13 mu g of LSD might be used safely in an investigation of repeated administrations. It remains to be determined whether the drug improves mood or cognition in individuals with symptoms of depression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available